Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BillionToOneBLLN -0.25%15 1-Year Share Buyback Ratio is -4.70 as of Jun. 2026. GuruFocus rates BLLN with a GF Score™ of 15/100. The stock has 4 warning signs investors should review. Among 147 Medical Diagnostics & Research companies, BillionToOne ranks worse than 53.06% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. BillionToOne's current 1-Year Share Buyback Ratio was -4.70%.
BLLN's 1-Year Share Buyback Ratio is ranked worse than 53.06% of 147
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.9
vs BLLN: -4.70
BillionToOne (NAS:BLLN) 1-Year Share Buyback Ratio Explanation
A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
BillionToOne 1-Year Share Buyback Ratio Related Terms
BLLN vs TWST, SHC, RDNT: 1-Year Share Buyback Ratio Comparison
For the Diagnostics & Research subindustry, BillionToOne's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BillionToOne 1-Year Share Buyback Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BillionToOne's 1-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where BillionToOne's 1-Year Share Buyback Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 1-Year Share Buyback Ratio of -4.70 mean?
BillionToOne (BLLN) has a 1-Year Share Buyback Ratio of -4.70 as of Jun. 2026. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for BillionToOne and its competitors. According to the industry distribution chart, BillionToOne ranks #78 out of 147 companies in the Medical Diagnostics & Research industry, placing it in the top 53.1%.
Is BillionToOne's 1-Year Share Buyback Ratio too high?
BillionToOne's current 1-Year Share Buyback Ratio is -4.70. Based on the distribution chart, BillionToOne ranks #78 out of 147 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, BillionToOne has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does BillionToOne's 1-Year Share Buyback Ratio compare to TWST and SHC?
According to the Medical Diagnostics & Research industry distribution chart, BillionToOne ranks #78 out of 147 companies for 1-Year Share Buyback Ratio. This places BillionToOne in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Share Buyback Ratio for a Medical Diagnostics & Research company?
A good 1-Year Share Buyback Ratio depends on the Medical Diagnostics & Research industry context. However, 1-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Share Buyback Ratio mean?
A high 1-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for BillionToOne and its competitors. BillionToOne's current 1-Year Share Buyback Ratio is -4.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BillionToOne stock overvalued right now?
BillionToOne (BLLN) has a current 1-Year Share Buyback Ratio of -4.70. The current 1-Year Share Buyback Ratio is -4.70. BillionToOne's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Share Buyback Ratio calculated?
1-Year Share Buyback Ratio is calculated from a company's financial statements. For BillionToOne (BLLN), the current 1-Year Share Buyback Ratio is -4.70 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
15GF Score
Get the complete analysis for BLLN
1-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLLN has been successfully added to your 
